GlassScriptPhysician profile
William Lineaweaver
NPI 1073695706
$2,362.48
in general payments reported to CMS, 2019-2025
14 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $249 · 2021: $74.27 · 2022: $6.57 · 2023: $120 · 2024: $125 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $451.73 | 2019-2025 | Novosorb Btm |
| Avita Medical Americas, LLC | $442.14 | 2019-2025 | Recell, Cohealyx, Permeaderm |
| Medline Industries LP | $285.02 | 2019-2025 | |
| Kerecis Limited | $203.45 | 2019-2022 | |
| Integra Lifesciences Corporation | $193.10 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Polarityte, INC. | $154.84 | 2019 | |
| Acera Surgical, INC. | $130.10 | 2019-2025 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $118.97 | 2019-2023 | Oasis, Acticoat 4" X 4", Versajet |
| Baxter Healthcare | $102.24 | 2019 | |
| Axogen | $90.19 | 2019 | |
| Tela Bio, INC. | $83.89 | 2019 | |
| Aroa Biosurgery Incorporated | $54.76 | 2025 | |
| Organogenesis INC. | $37.01 | 2021-2024 | |
| Tei Biosciences INC | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lineaweaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.